4502 — Takeda Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Takeda Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	3,569,006	4,027,478	4,263,762	4,581,551	4,505,720
Cost of Revenue
Gross Profit	2,462,160	2,783,406	2,837,084	3,001,334	2,934,132
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	3,123,808	3,494,185	4,014,490	4,224,494	4,096,959
Operating Profit	445,198	533,293	249,272	357,057	408,761
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	302,571	375,090	52,791	175,084	260,189
Provision for Income Taxes
Net Income After Taxes	230,166	317,038	144,197	108,143	192,026
Minority Interest
Net Income Before Extraordinary Items
Net Income	230,059	317,017	144,067	107,928	191,762
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	230,059	317,017	144,067	107,928	191,762
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	194	211	168	146	122
Dividends per Share